SH3PXD2A: A Potential Drug Target and Biomarker (G9644)

Target Name: SH3PXD2A

NCBI ID: G9644

SH3PXD2A

SH3PXD2A: A Potential Drug Target and Biomarker

SH3PXD2A, also known as SH3 and PX domain-containing protein 2A (isoform 1), is a protein that has been identified as a potential drug target and biomarker. Its unique structure and function have made it an intriguing target for researchers to study.

The protein SH3PXD2A is a 21 kDa protein that is expressed in various tissues, including brain, heart, and liver. It is composed of two domains: the SH3 domain and the PX domain. The SH3 domain is a highly conserved protein that is known for its ability to form a hydrogen bond network, which is involved in various cellular processes, including cell signaling and interactions. The PX domain is a unique protein that is found in a variety of tissues and is involved in the regulation of cellular processes, including cell growth, differentiation, and inflammation.

One of the key features of SH3PXD2A is its ability to interact with various molecules, including transcription factors, RNA-binding proteins, and protein kinases. This interaction between the protein and other molecules suggests that SH3PXD2A could be a useful drug target for a variety of diseases.

One of the potential benefits of targeting SH3PXD2A is its potential to treat various types of cancer. Cancer is a leading cause of death worldwide, and there is a need for new, effective treatments to address this issue. SH3PXD2A has been shown to play a role in the development and progression of several types of cancer, including neurobladder cancer, breast cancer, and colon cancer.

In addition to its potential as a cancer drug, SH3PXD2A has also been identified as a potential biomarker for several types of cancer. The SH3PXD2A protein has been shown to be expressed in various types of cancer cells and has been used as a marker for cancer diagnosis and monitoring. This suggests that SH3PXD2A could be a useful biomarker for cancer detection and treatment.

Another potential benefit of targeting SH3PXD2A is its effects on inflammation. Chronic inflammation is a major risk factor for a variety of diseases, including heart disease and neurological diseases. SH3PXD2A has been shown to play a role in the regulation of inflammation and has been shown to have anti-inflammatory effects. This suggests that SH3PXD2A could be a useful target for treatments aimed at reducing inflammation.

In conclusion, SH3PXD2A is a protein with a unique structure and function that has the potential to be a drug target and biomarker. Its interaction with various molecules and its ability to play a role in the development and progression of cancer make it an intriguing target for researchers to study. Further research is needed to fully understand the protein's role and its potential as a drug and biomarker.

Protein Name: SH3 And PX Domains 2A

Functions: Adapter protein involved in invadopodia and podosome formation, extracellular matrix degradation and invasiveness of some cancer cells. Binds matrix metalloproteinases (ADAMs), NADPH oxidases (NOXs) and phosphoinositides. Acts as an organizer protein that allows NOX1- or NOX3-dependent reactive oxygen species (ROS) generation and ROS localization. In association with ADAM12, mediates the neurotoxic effect of amyloid-beta peptide

The "SH3PXD2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3PXD2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets